EMBARGOED FOR RELEASE: Friday October 18, 2013, 8 a.m. Eastern Time
Philadelphia, PA, October 17, 2013 — Longevity Biotech, Inc. today announced that its licensor, the Wisconsin Alumni Research Foundation (WARF), has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent covering the company’s Hybridtide® peptide stabilization platform technology. Upon issuance, the new patent will provide Longevity Biotech, Inc., its exclusive licensee, with intellectual property protection that covers platform compositions that create robust protease resistance. Protease stability is a key challenge facing traditional biologic drugs, which are often rendered inactive in a matter of minutes. The Hybridtide® platform retains biological and therapeutic activity while conferring significant protection from a variety of biologically relevant proteases. Protease susceptibility has also been a primary hurdle in the oral delivery of peptide therapeutics. Longevity is currently investigating the ability to deliver Hybridtide® based orally delivered peptide therapeutics.
“The ability to reduce protease susceptibility for biologic drugs without encumbering critical surface interactions is a tremendous advantage from a number of perspectives.” said Scott Shandler, PhD, president of Longevity Biotech, Inc. “We believe that this newly issued U.S. patent reinforces our already substantial patent portfolio covering the Hybridtide® platform as well as specific applications across multiple therapeutic areas currently in preclinical development (Diabetes, Cardiovascular, Oncology, Antiviral and Neurological).” The patent is expected to issue in the next two months.
ABOUT LONGEVITY BIOTECH, INC
Longevity Biotech, Inc. is a preclinical stage biopharmaceutical company developing numerous innovative preclinical programs based on the patented Hybridtide® scaffold technology. Specific programs include, Type II Diabetes, Pulmonary Hypertension, Breast Cancer, anti-viral HIV products and most recently Parkinson’s Disease. Each program has a unique set of attributes leading to either first or best in class product profiles in their respective indication.
The Hybridtide® advantage enables longer-acting therapeutic peptides as compared to current state of the art clinically approved therapeutics which currently generate billions of dollars in annual global sales. The Hybridtide® technology is applicable to virtually all peptides and is available for partnership and/or co-development efforts as appropriate. For more information, visit http://www.longevitybiotech.com
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding the results of current preclinical experiments and the effectiveness. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Longevity Biotech, Inc business and prospects, including the risks that Longevity Biotech, Inc may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of products mentioned herein; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the Hybridtide® platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
Longevity Biotech, Inc
Scott Shandler, President & CEO
Longevity Biotech, Inc
Tel: +1 215-689-1042
SOURCE Longevity Biotech, Inc
Biotechnology; Patent; Medicine; Therapeutics; Preclinical Research; Philadelphia; University of Wisconsin – Madison; Diabetes; Cardiovascular Disease; Pulmonary Disease; HIV; Neurological Disorders; Oncology;